1. Search Result
Search Result
Results for "

viral infectivity

" in MedChemExpress (MCE) Product Catalog:

64

Inhibitors & Agonists

2

Screening Libraries

1

Fluorescent Dyes

1

Biochemical Assay Reagents

1

Peptides

3

Inhibitory Antibodies

4

Natural
Products

5

Isotope-Labeled Compounds

1

Click Chemistry

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14397
    Indomethacin
    Maximum Cited Publications
    76 Publications Verification

    Indometacin

    COX Antibiotic Influenza Virus Bacterial Inflammation/Immunology Cancer
    Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research .
    Indomethacin
  • HY-100442
    Paquinimod
    30+ Cited Publications

    ABR-215757; ABR 25757

    SARS-CoV Metabolic Disease Inflammation/Immunology
    Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .
    Paquinimod
  • HY-112163
    Zotatifin
    5+ Cited Publications

    eFT226

    Eukaryotic Initiation Factor (eIF) SARS-CoV Apoptosis Infection Cancer
    Zotatifin (eFT226) is a potent, selective, and well-tolerated eIF4A inhibitor. Zotatifin promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5’-UTRs (IC50=2 nM) and interferes with the assembly of the eIF4F initiation complex . Zotatifin shows robust antiviral effects, it effectively reduces viral infectivity by inhibiting SARS-CoV-2 NP protein biogenesis (IC90=37 nM) . Zotatifin induces cell apoptosis .
    Zotatifin
  • HY-145586

    ZSP1273

    Influenza Virus DNA/RNA Synthesis Infection
    Onradivir (ZSP1273) is an orally active antiviral agent targeting influenza A virus RNA polymerase PB2 subunit with an IC50 of 0.562 nM. Onradivir inhibits cap binding to influenza A virus RNA polymerase PB2 subunit, suppresses viral replication, reduces viral titres and RNA loads, and inhibits influenza A virus infection. Onradivir maintains high survival rates in influenza A virus-infected mice, and reduces influenza A virus titers in a murine model. Onradivir can be used for the research of influenza A virus infection .
    Onradivir
  • HY-N7922
    Urolithin M5
    1 Publications Verification

    Decarboxyellagic acid

    Influenza Virus p38 MAPK EGFR Akt Reactive Oxygen Species (ROS) Apoptosis Infection Neurological Disease
    Urolithin M5 (Decarboxyellagic acid) is an orally active influenza virus neuraminidase inhibitor and neuroprotective agent, with IC50 values of 174.8 μM (HK68), 191.5 μM (pdm09), 243.2 μM (WSN) and 257.1 μM (PR8) against four influenza virus neuraminidases, respectively. Urolithin M5 inhibits viral neuraminidase activity, thereby blocking influenza virus replication (including oseltamivir (HY-13317)-resistant strains), protecting infected mammals from death and improving pulmonary edema. Urolithin M5 forms a hydrogen-bond stabilized complex with IGF1R, and binds to MAPK14, AKT1, NFKB1 and EGFR. Urolithin M5 reduces reactive oxygen species production, inhibits neuronal apoptosis, restores mitochondrial transmembrane potential, and promotes neurite outgrowth of damaged neuronal cells. Urolithin M5 can be used in research related to influenza virus infection and Alzheimer's disease .
    Urolithin M5
  • HY-W725179

    EBV Cancer
    VK-2019 is an orally bioavailable selective inhibitor of EBNA1. By binding to the protein-DNA interface to interfere with the recruitment and anchoring of the viral DNA replication machinery, VK-2019 effectively blocks the replication and proliferation of EBV in latently infected cells. VK-2019 reduces the copy number and gene expression level of Epstein-Barr virus in tumor cells, decreases the number of EBER-positive cells, and exhibits significant antiviral, immunomodulatory and antiproliferative activities. VK-2019 successfully inhibits tumor growth in EBV-dependent xenograft models. VK-2019 has favorable systemic exposure and acceptable safety profiles, and is widely used in research on advanced nasopharyngeal carcinoma and various EBV-associated cancers .
    VK-2019
  • HY-N0677A
    Kalii Dehydrographolidi Succinas
    1 Publications Verification

    Potassium dehydroandrographolide succinate

    Antibiotic Infection Inflammation/Immunology
    Kalii Dehydrographolidi Succinas (Potassium dehydroandrographolide succinate) is an antibiotic. Kalii Dehydrographolidi Succinas exerts immunostimulatory, anti-infective and anti-inflammatory effects . Kalii Dehydrographolidi Succinas shows potential for research on viral pneumonia and viral upper respiratory tract infections .
    Kalii Dehydrographolidi Succinas
  • HY-145119

    SARS-CoV Infection
    GS-621763 is an orally available precursor to GS-441524 that exhibits anti-SARS-CoV-2 viral activity in mice. GS-621763 reduces viral load to undetectable levels in ferrets infected with SARS-CoV-2 .
    GS-621763
  • HY-P991446

    Influenza Virus Infection
    MEDI-8852 is a human IgG1 monoclonal antibody against influenza A virus hemagglutinin (HA). MEDI-8852 binds to the conserved HA stalk epitope and neutralizes viral infectivity. MEDI-8852 reduces viral titers in mouse lung tissues. MEDI-8852 is applicable to research related to pandemic influenza . Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
    MEDI-8852
  • HY-14397A
    Indomethacin sodium hydrate
    Maximum Cited Publications
    76 Publications Verification

    Indometacin sodium hydrate

    COX Bacterial Influenza Virus Antibiotic Infection Neurological Disease Inflammation/Immunology Cancer
    Indomethacin (Indometacin) sodium hydrateis a orally active and BBB-permeable COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin sodium hydrateis has anticancer activity and anti-infective activity. Indomethacin sodium hydrateis can be used for cancer, inflammation and viral infection research .
    Indomethacin sodium hydrate
  • HY-N0677
    Dehydroandrographolide succinate
    1 Publications Verification

    Influenza Virus Prostaglandin Receptor Akt GSK-3 Infection Inflammation/Immunology Cancer
    Dehydroandrographolide succinate can be extracted from herbal medicine Andrographis paniculata (Burm f) Nees, is widely used in research for viral pneumonia and viral upper respiratory tract infections because of its immunostimulatory, anti-infective and anti-inflammatory effect. Dehydroandrographolide succinate exerts antithrombotic effect. Dehydroandrographolide succinate significantly inhibits the platelet aggregation rate (ED50 = 386.9 mg/kg) by decreasing TXB2 levels. Dehydroandrographolide succinate mitigates muscle astrophy via the Akt/GSK3β and MuRF-1 pathways .
    Dehydroandrographolide succinate
  • HY-172760

    SARS-CoV Infection
    CIM-834 is an orally effective inhibitor of SARS-CoV-2 membrane protein. CIM-834 can prevent the assembly of infectious virus particles without inhibiting the synthesis of viral RNA. CIM-834 can reduce the viral titer in the lungs of SCID mice infected nasally with SARS-CoV-2, block the spread of SARS-CoV-2 among Syrian hamsters, and inhibit the replication of SARS-CoV-2 (including variants) and SARS-CoV. CIM-834 can be used in related research on COVID-19 .
    CIM-834
  • HY-169092

    SARS-CoV Virus Protease Infection
    PF-07957472 (Compound 4) is an orally active and selective SARS-CoV-2 papain-like protease (PLpro) inhibitor, with a Ki of 2 nM against SARS-CoV-2 PLpro. PF-07957472 reduces SARS-CoV-2 viral titers in the lungs of infected mice and inhibits SARS-CoV-2-induced cytopathic effects in cells. PF-07957472 can be used for the research of COVID-19 .
    PF-07957472
  • HY-175469

    Influenza Virus Infection
    VNT-101 is an orally active influenza A (IAV) inhibitor. VNT-101 disrupts NP-NP PPI to block NP oligomerization and destabilize the viral ribonucleoprotein (RNP) complex, with potent antiviral activity across multiple influenza A subtypes. VNT-101 exhibits EC50 values of 4-5 nM in cellular cytopathic effect (CPE) assay, 4-8 nM in neuraminidase (NA) assay, and 21-45 nM in RNP assay. VNT-101 demonstrates robust in vivo antiviral efficacy in mice infected with lethal H1N1 virus. VNT-101 can be used for the study of influenza A infection .
    VNT-101
  • HY-131944

    Apoptosis HSV Infection Cancer
    S-Acetylglutathione is a derivative of Glutathione (HY-D0187). S-Acetylglutathione is stable in blood, and can be converted to glutathione by intracellular thioesterases. S-Acetylglutathione restores the intracellular glutathione content in glutathione synthetase deficient fibroblasts. S-Acetylglutathione exhibits antiviral efficacy in HSV-1 infected model through inhibition of viral replication. S-Acetylglutathione induces apoptosis in cancer cells MOLT4 and UKF-NB-3 .
    S-Acetylglutathione
  • HY-B0402S

    1-Adamantanamine-d15; 1-Aminoadamantane-d15

    Influenza Virus Orthopoxvirus SARS-CoV Apoptosis Infection Neurological Disease Cancer
    Amantadine-d15 is the deuterium labeled Amantadine. Amantadine (1-Adamantanamine) is an antiviral agent with activity against influenza A viruses. Amantadine blocks the proton flow through the M2 ion channel (M2 proton channel of influenza A) and thus prevents the release of viral RNA into the cytoplasm of the infected cells. Amantadine is an antiparkinsonian agent .
    Amantadine-d15
  • HY-102014

    HIV Infection
    RN-18 is a HIV-1 viral infectivity factor (HIV-1 Vif) inhibitor with an IC50 of 6 μM in nonpermissive H9 cells.
    RN-18
  • HY-106055

    HIV Inflammation/Immunology
    Murabutide is a safe synthetic immunomodulator. Murabutide can reduce CD4 and CCR5 receptor expression and secrete high levels of beta-chemokines. Murabutide enhances nonspecific resistance against viral infections. Murabutide did not affect virus entry, reverse transcriptase activity or early proviral DNA formation in the cytoplasm of infected cells .
    Murabutide
  • HY-14397R

    Indometacin (Standard)

    Reference Standards COX Antibiotic Influenza Virus Bacterial Inflammation/Immunology Cancer
    Indomethacin (Standard) is the analytical standard of Indomethacin. This product is intended for research and analytical applications. Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research .
    Indomethacin (Standard)
  • HY-161844

    SARS-CoV Dengue Virus Infection
    Virapinib is a macropinocytosis inhibitor with antiviral activity. Virapinib exhibits broad-spectrum antiviral activity against SARS-CoV-2, monkeypox virus, tick-borne encephalitis virus, and Ebola pseudotyped vesicular stomatitis virus, and it enhances Dengue Virus infection. Virapinib blocks viral entry by inhibiting macropinocytosis, reduces syncytium formation in SARS-CoV-2-infected cells, and impairs cellular entry of SARS-CoV-2 variants. Virapinib upregulates the expression of genes related to sterol biosynthesis. Virapinib can be used in studies related to COVID-19, monkeypox, tick-borne encephalitis, and Ebola virus infection .
    Virapinib
  • HY-12946

    Glucocorticoid Receptor Cytochrome P450 HCV Protease Infection Inflammation/Immunology
    BI 653048, a chemical probe, is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC50 value of 55 nM . BI 653048 inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms’ activity and reduces affinity for the hERG ion channel (IC50>30 μM) . BI 653048 (Compound 103) is also a HCV NS3 protease inhibitor that can reduce viral loads infected with the hepatitis C virus .
    BI 653048
  • HY-100442S1

    ABR-215757-d5-1; ABR 25757-d5-1

    SARS-CoV Isotope-Labeled Compounds Metabolic Disease Inflammation/Immunology
    Paquinimod-d5-1 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .
    Paquinimod-d5-1
  • HY-178137

    SARS-CoV Hepatitis E Virus (HEV) Filovirus Infection
    SCR007 is a synthetic carbohydrate receptor (SCR) with broad-spectrum antiviral activity. SCR007 inhibits the entry of enveloped viruses across multiple families (Coronaviridae: SARS-CoV-1, SARS-CoV-2, MERS-CoV; Filoviridae: EBOV, MARV; Paramyxoviridae: NiV, HeV) and the glycosylated nonenveloped rotavirus. SCR007 binds viral envelope N-glycans, blocking viral binding to host cells or both binding and membrane fusion. SCR007 exerts prophylactic effects in hACE2 mice infected with SARS-CoV-2. SCR007 can be used for the study and prevention of enveloped virus pandemics .
    SCR007
  • HY-178690

    MyD88 IFNAR Infection Inflammation/Immunology
    MyD88-IN-4 is a MyD88 inhibitor. MyD88-IN-4 exerts antiviral effects by up-regulating IFN-β, and anti-inflammatory effects by inhibiting pro-inflammatory cytokine production. MyD88-IN-4 prevents MyD88 homodimer formation and its interaction with IRF3/IRF7. MyD88-IN-4 demonstrates efficacy against encephalitic alphavirus infections by reducing viral replication and improving survival in VEEV TC-83-infected mouse models. MyD88-IN-4 can be used for the study of alphavirus infections, bacterial toxin-related diseases, and sepsis .
    MyD88-IN-4
  • HY-159925

    Cyclic GMP-AMP Synthase Infection Inflammation/Immunology
    QKY-613 is a prodrug that enhances immune surveillance by targeting nucleic acid modification pathways. QKY-613 promotes the selective incorporation of 6mdA (N6-methyldeoxyadenosine) into viral DNA, enhancing the phase separation potential of DNA, thereby increasing the activation of cGAS and strengthening host immune surveillance. In virus-infected mouse models, QKY-613 significantly reduced mortality in aged mice. QKY-613 holds promise for research on nucleic acid modification-based immune surveillance mechanisms .
    QKY-613
  • HY-111311

    Bacterial Drug Derivative Infection
    NVC-422 is a N-chlorotaurine analog, virucidal agent, antibacterial agent. NVC-422 exhibits virucidal activity against Ad5 by the oxidative inactivation of key viral proteins (fiber and hexon), leading to the loss of viral integrity and infectivity. NVC-422 is shown to be highly effective in killing all microbial strains tested, including antibiotic-resistant S. aureus and E. faecium. NVC-422 can be used in the research of adenoviral conjunctivitis .
    NVC-422
  • HY-147014

    CMV Orthopoxvirus Infection
    Cyclic HPMPC is a potent antiviral agent. Cyclic HPMPC can increase arterial oxygen saturation levels in lethal vaccinia virus (IHD strain)-infected mice. Cyclic HPMPC improves the outcome of congenital guinea pig cytomegalovirus (GPCMV) infection and decreases viral replication in guinea pig model .
    Cyclic HPMPC
  • HY-15034

    INDOMETHACIN SODIUM

    COX Antibiotic Influenza Virus Bacterial Inflammation/Immunology Cancer
    Indomethacin (Indometacin) sodium is a potent, orally active COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin sodium has anticancer activity and anti-infective activity. Indomethacin sodium can be used for cancer, inflammation and viral infection research. .
    Indomethacin sodium
  • HY-145586A

    ZSP1273 monohydrate

    Influenza Virus DNA/RNA Synthesis Infection
    Onradivir (ZSP1273) monohydrate is an orally active antiviral agent targeting influenza A virus RNA polymerase PB2 subunit with an IC50 of 0.562 nM. Onradivir monohydrate inhibits cap binding to influenza A virus RNA polymerase PB2 subunit, suppresses viral replication, reduces viral titres and RNA loads, and inhibits influenza A virus infection. Onradivir monohydrate maintains high survival rates in influenza A virus-infected mice, and reduces influenza A virus titers in a murine model. Onradivir monohydrate can be used for the research of influenza A virus infection .
    Onradivir monohydrate
  • HY-172350

    SARS-CoV Virus Protease Interleukin Related Infection
    WEHI-P8 is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor with an IC50 of 12 nM and a Kd of 9.0 nM. WEHI-P8 reduces viral load, body weight loss, pulmonary inflammation, immune cell infiltration and pro-inflammatory mediator levels in SARS-CoV-2-infected mice. WEHI-P8 prevents pulmonary hemorrhage, immune cell infiltration, fibrotic remodeling and neuroinflammation, and improves cognitive function in a mouse model of post-acute sequelae of SARS-CoV-2 infection (PASC). WEHI-P8 is applicable for the research of COVID-19 and PASC .
    WEHI-P8
  • HY-178135

    SARS-CoV Filovirus Hepatitis E Virus (HEV) Infection
    SCR005 is a synthetic carbohydrate receptor (SCR) with broad-spectrum antiviral activity. SCR005 inhibits the entry of enveloped viruses across multiple families (Coronaviridae: SARS-CoV-1, SARS-CoV-2, MERS-CoV; Filoviridae: EBOV, MARV; Paramyxoviridae: NiV, HeV) and the glycosylated nonenveloped rotavirus. SCR005 binds viral envelope N-glycans, blocking viral binding to host cells or both binding and membrane fusion. SCR005 exerts prophylactic effects in hACE2 mice infected with SARS-CoV-2. SCR005 can be used for the study and prevention of enveloped virus pandemics .
    SCR005
  • HY-14397G

    Indometacin

    Antibiotic Influenza Virus Bacterial COX Inflammation/Immunology Cancer
    Indomethacin (GMP) is Indomethacin (HY-14397) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research .
    Indomethacin
  • HY-175165

    Enterovirus Infection
    Jun6504 is an enterovirus 2C inhibitor. Jun6504 shows potent and broad-spectrum antiviral activity against multiple strains of EV-D68 (EC50 = 250 nM), EV-A71 (EC50 = 502.4 nM), and CVB3 (EC50 = 1049 nM). Jun6504 improves paralysis score and weight gain in a neonatal mouse model of EV-D68 infection. Jun6504 reduces viral titers in the spinal cord and the infected quadriceps muscle. Jun6504 can be used for EV-D68 antiviral research .
    Jun6504
  • HY-12946A

    Glucocorticoid Receptor Cytochrome P450 HCV Protease Infection Inflammation/Immunology
    BI 653048 phosphate is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC50 value of 55 nM . BI 653048 phosphate inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms’ activity and reduces affinity for the hERG ion channel (IC50>30 μM) . BI 653048 phosphate is extracted from patent WO2005028501A1 (Compound 103), is also a HCV NS3 protease inhibitor that can reduce viral loads infected with the hepatitis C virus .
    BI 653048 phosphate
  • HY-120157

    HIV Infection
    Vif-ElonginC interaction inhibitor 1 (compound VEC-5) is a potent Vif inhibitor. Vif-ElonginC interaction inhibitor 1 can restrict HIV-1 in Vif-nonpermissive cells. Vif-ElonginC interaction inhibitor 1 can protect A3G, APOBEC3C (A3C), and APOBEC3F (A3F) from Vif-mediated degradation and drastically inhibit Vif function through blocking the interaction between Vif and ElonginC. Vif-ElonginC interaction inhibitor 1 enhances A3G incorporation into HIV-1 virions to reduce viral infectivity .
    Vif-ElonginC interaction inhibitor 1
  • HY-141841

    SARS-CoV Infection
    SARS-CoV-2-IN-7 inhibits viral replication with a nanomolar IC50 value (844 nM) in SARS-CoV-2-infected Vero E6 cells.
    SARS-CoV-2-IN-7
  • HY-161691

    Filovirus Infection
    EBOV-IN-9 (compound 2b) is Diphyllin derivative that blocks Ebola viral entry with an EC50 of 40 nM. EBOV-IN-9 against EBOV-infected monocyte-derived macrophages with an EC50 of 107 nM .
    EBOV-IN-9
  • HY-100442S

    ABR-215757-d5; ABR 25757-d5

    SARS-CoV Isotope-Labeled Compounds Metabolic Disease
    Paquinimod-d5 is a deuterated analog of Paquinimod (HY-100442). Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .
    Paquinimod-d5
  • HY-100442R

    ABR-215757 (Standard); ABR 25757 (Standard)

    Reference Standards SARS-CoV Metabolic Disease Inflammation/Immunology
    Paquinimod (Standard) is the analytical standard of Paquinimod. This product is intended for research and analytical applications. Paquinimod (ABR 215757) is a specific and orally active inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice .
    Paquinimod (Standard)
  • HY-16740B

    A-5021 sodium

    DNA/RNA Synthesis Infection
    Eprociclovir sodium is an antiviral drug with nucleoside analogues. The triphosphate form of Eprociclovir sodium is converted into the active form within virus-infected cells by the virus and possible cellular enzymes, including the viral thymidine kinase, thereby inhibiting the activity of the viral DNA polymerase. The primary activity of Eprociclovir sodium is against herpes viruses, including but not limited to cytomegalovirus (CMV) and herpes simplex virus (HSV). Eprociclovir sodium can be used in studies interfered with by sensitive viruses .
    Eprociclovir sodium
  • HY-16740

    A-5021

    DNA/RNA Synthesis Infection
    Eprociclovir is an antiviral drug with nucleoside analogues. The triphosphate form of Eprociclovir is converted into the active form within virus-infected cells by the virus and possible cellular enzymes, including the viral thymidine kinase, thereby inhibiting the activity of the viral DNA polymerase. The primary activity of Eprociclovir is against herpes viruses, including but not limited to cytomegalovirus (CMV) and herpes simplex virus (HSV). Eprociclovir can be used in studies interfered with by sensitive viruses .
    Eprociclovir
  • HY-16740A

    A-5021 potassium

    DNA/RNA Synthesis Infection
    Eprociclovir potassium is an antiviral drug with nucleoside analogues. The triphosphate form of Eprociclovir potassium is converted into the active form within virus-infected cells by the virus and possible cellular enzymes, including the viral thymidine kinase, thereby inhibiting the activity of the viral DNA polymerase. The primary activity of Eprociclovir potassium is against herpes viruses, including but not limited to cytomegalovirus (CMV) and herpes simplex virus (HSV). Eprociclovir potassium can be used in studies interfered with by sensitive viruses .
    Eprociclovir potassium
  • HY-174433

    Influenza Virus Infection
    PAN endonuclease-IN-4 (Compound 41) is an inhibitor of PAN endonuclease with antiviral properties. PAN endonuclease-IN-4 is the prodrug of 39-(S). PAN endonuclease-IN-4 can significantly suppress viral replication in an A/WSN/33 infected mouse model .
    PAN endonuclease-IN-4
  • HY-155527

    SARS-CoV Infection
    SARS-CoV-2 Mpro-IN-9 (compound c7) is a nonpeptidic, noncovalent SARS-CoV-2 M pro inhibitor (IC50=0.085 μM), with improved physicochemical and drug metabolism and pharmacokinetics (DMPK) properties. SARS-CoV-2 Mpro-IN-9 inhibits viral replication (EC50=1.10 μM) in SARS-CoV-2-infected Vero E6 cells, while exhibits low cytotoxic effects (CC50>50 μM) .
    SARS-CoV-2 Mpro-IN-9
  • HY-173338

    DNA/RNA Synthesis Infection
    MSRV-IN-1 (Compound M3) is an inhibitor targeting aquatic rhabdoviruses (such as MSRV, SVCV and IHNV). Its IC50 values for inhibiting MSRV, SVCV and IHNV are 0.92 μM, 2.92 μM and 2.78 μM respectively. MSRV-IN-1 does not act directly on the virions but rather inhibits viral replication by altering the cell cycle arrest state in the S phase induced by the virus and disrupting the viral replication environment. When administered intraperitoneally at a dose of 20 mg/kg, MSRV-IN-1 can significantly increase the survival rate of largemouth bass infected with MSRV by 35.98% and reduce the viral loads in the liver, spleen and kidney. MSRV-IN-1 can be used in the research of diseases related to rhabdoviruses in aquaculture .
    MSRV-IN-1
  • HY-14397S2

    Bacterial Influenza Virus Antibiotic COX Isotope-Labeled Compounds Inflammation/Immunology Cancer
    Indometacin-d7 is deuterated labeled Indomethacin (HY-14397). Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research .
    Indometacin-d7
  • HY-14397S3

    Indometacin-13C6

    Isotope-Labeled Compounds COX Antibiotic Influenza Virus Bacterial Inflammation/Immunology Cancer
    Indomethacin- 13C6 (Indometacin- 13C6) is 13C labeled Indomethacin. Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research .
    Indomethacin-13C6
  • HY-P10653

    HCV HIV Infection
    C5A is a microbicidal peptide, anti-hepatitis C virus (HCV), and anti-HIV agent. C5A disrupts the membrane integrity of the HIV virion as well as the integrity of the conical capsid core that surrounds the viral genome. C5A inhibits in vitro infectivity of a broad range of primary HIV isolates in various primary target cells. C5A protects mice against vaginal and rectal HIV challenges .
    C5A
  • HY-129678

    HIV Protease HIV Infection
    UK-88947 hydrochloride is a protease inhibitor with activity in inhibiting the replication of human immunodeficiency virus HIV-1. UK-88947 hydrochloride can be added to cells before infection to block the early steps of HIV-1 replication. The use of UK-88947 hydrochloride shows its specific inhibitory effect on HIV-1. At the same time, when the virus infects cells, it inhibits the action of viral protease and affects the virus replication process .
    UK-88947 hydrochloride
  • HY-149058

    Influenza Virus Infection
    Neuraminidase-IN-13 (Compound 10) is a neuraminidase inhibitor with antiviral activity and low cytotoxicity. Neuraminidase-IN-13 significantly inhibits NDV infection of Vero cells by preventing the release of viral particles from infected cells . Neuraminidase-IN-13 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    Neuraminidase-IN-13

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: